Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06783803

Application of Linkage Analysis in the Identification of Novel Hereditary Factors in Familial Aneurysms

The aim of this study is to describe the effectiveness of the application of Linkage Analysis, compared to the standard procedures currently provided by the italian NHS, in the identification of thoracic aortic aneurysms and dissection (TAAD) transmission markers in individuals with familial TAAD.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Cardiovascular Genetic Centre

San Donato Milanese, Milan, 20097, Italy

About this study

According to current guidelines, it is important to screen first-degree relatives of patients with familial thoracic aortic aneurysm and dissection (FTAAD) using imaging techniques in order to detect any undiagnosed or asymptomatic cases. The current diagnostic methods for FTAAD involve clinical and instrumental diagnosis. In addition to these methods, genetic analysis through DNA testing, using a blood sample has become an essential tool. The use of massive parallel sequencing (NGS) of multiple genes or the entire exome (Whole Exome Sequencing - WES) is considered the gold standard for genetic diagnosis of FTAAD. However, it should be noted that linkage studies are not currently included in the diagnostic protocols of the Italian National Health System, although they may be helpful in complex familial cases where DNA sequencing has not provided conclusive evidence.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with ascending thoracic aortic aneurysms in the absence of a mutation identified by WES
  • Subjects with small and medium artery aneurysms in the absence of a mutation identified by WES
  • Relatives of individuals with ascending thoracic aortic aneurysms in the absence of a mutation identified by WES
  • Relatives of individuals with ascending thoracic aortic aneurysms in the absence of a mutation identified by WES
  • Signed informed consent

Exclusion criteria

  • Subjects wit syndromic FTAAD with WES identified gene mutation
  • Subjects wit non-syndromic FTAAD with WES identified gene mutation

Treatment and study plan

Linkage Analysis

Diagnostic Test

WES-Linkage analysis in families with FTAAD in follow-up in an Italian reference centre for genetic aorthopathies

Primary outcomes

  1. DNA sequences in FTAAD

    Time frame: 16 months

    Identify those chromosome regions containing the DNA sequences responsible for each enrolled member of FTAAD families

Secondary outcomes

  1. Mutations associated with Mendelian and monogenic diseases

    Time frame: 24 months

    Identification of potential sites for the location of the responsible gene and mutations associated with Mendelian and monogenic diseases.

Sponsors and collaborators

Lead sponsor

IRCCS Policlinico S. Donato

Other

Collaborators

  • IRCCS Ospedale San Raffaele

Registry information

Acronym: ORPHADIAG

Important dates

Study start
2024
Primary completion
2029
Study completion
2029
First posted
Jan 20, 2025
Registry last updated
Jan 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.